ストックスクリーナーアプリを入手
1,183.46
0.13%
1.57
アフターアワーズ：
1183.56
0.10
+0.01%
Lilly Eli Co (LLY) 最新ニュース
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines - Stocktwits
FDA Expands Approval of Eli Lilly's Olumiant for Severe Alopecia Areata in Children (LLY) - GuruFocus
Eli Lilly (LLY) Gains FDA Nod for Olumiant in Pediatric Alopecia Areata - GuruFocus
Lilly's pill is FDA-approved for teens as young as 12 with severe immune-related hair loss - Stock Titan
Eli Lilly stock closes at USD 1,181.89, up 2.68 percent at the closing bell - AD HOC NEWS
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says - Reuters
Eli Lilly gives a helping hand to Kenosha-area food pantries - Journal Times
Lilly wins approval for once-weekly insulin shot - STAT
Lilly ordered to pay Nektar $90M in damages over rezpeg dispute - FirstWord
Why Is Eli Lilly (NYSE:LLY) Drawing Fresh NYSE Attention? - Kalkine Media
Jury awards Nektar Therapeutics $90M in rezpeg dispute with Eli Lilly - app.dealroom.co
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury FundsEli Lilly (NYS - benzinga.com
Eli Lilly stock gains 2.86 percent as guidance rises - AD HOC NEWS
Editorial: Lilly CEO calls on city, state to get serious about quality of life - Indianapolis Business Journal
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly - Investing.com Canada
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? - The Motley Fool
FDA approves Lilly’s Onswik for type 2 diabetes in adults - Yahoo
91-year-old investor sees healthcare titan doubling in 3 years - thestreet.com
Eli Lilly and Co. stock gains 3.51 percent ahead of the open - AD HOC NEWS
Jurisdictional Skepticism Puts Eli Lilly Appeal On Thin Ice - Law360
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit - Law360
Eli Lilly (LLY) Stock Is Up, What You Need To Know - Yahoo Finance Australia
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
Medicare just handed Eli Lilly a massive weight-loss win - sg.finance.yahoo.com
Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact - medcitynews.com
FDA approves Eli Lilly's once-weekly insulin On... - Pluang
Eli Lilly and InnoCare sign drug discovery deal worth up to $3.35B - qz.com
Eli Lilly and Company (NYSE:LLY) Anchors Healthcare Focus on Deals and Clearances - Kalkine Media
Lilly Wins FDA Nod For Weekly Insulin, Signs $3.25 Billion InnoCare Pact - benzinga.com
Lilly’s Ricks says state needs to emphasize quality of life, health care - dailyjournal.net
Lilly extends China innovation push in $3.35B Innocare deal - BioWorld News
FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes - Dealroom
InnoCare and Lilly ink deal worth up to $3.35 billion across five drug targets - The Pharma Letter
US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes - Reuters
Eli Lilly Rises After FDA Approval for Once-Weekly Diabetes Insulin - Quiver Quantitative
How Is Lilly (NYSE:LLY) Broadening Its S&P 500 Pipeline Today? - Kalkine Media
Healthcare is a great defensive sector to be in when the rest of the market is crapping in their pants! - Moomoo
Eli Lilly and Co Stock (LLY) Moved Up by 3.73% on Sep 24: A Full Analysis - TradingKey
InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly - Pharmaceutical Executive
Eli Lilly Stock Price Today (LLY) | NYSE - TechGraph
Governor Abbott Delivers Remarks At Lilly Groundbreaking In Houston - Texas Border Business
Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare - Pharmaceutical Technology
LLY Looks 26.0% Undervalued on GF Value™ After FDA Approval of O - GuruFocus
Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal - pmlive.com
LLY Looks 26.0% Undervalued on GF Value™ After FDA Approval of W - GuruFocus
Eli Lilly signs deal worth up to USD 3.35bn with China's InnoCare - medwatch.com
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes - Eli Lilly
Lilly's FDA-approved weekly insulin could mean over 300 fewer shots a year than daily insulin - Stock Titan
InnoCare and Eli Lilly strike research collaboration worth up to $3.35B - app.dealroom.co
InnoCare Pharma partners with Eli Lilly in drug research deal - China Daily
InnoCare Pharma Partners with Eli Lilly on New Drug Development, Potential Milestones Up to $3.25 Billion - finance.biggo.com
Lilly reaches $3.35B deal with China's InnoCare - breakingthenews.net
Eli Lilly and Co. stock heads into the open after a 1.64 percent drop - AD HOC NEWS
Eli Lilly, InnoCare Pharma Partner on Drug Research, Development - marketscreener.com
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion - Reuters
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines - The Manila Times
Eli Lilly stock ends the day 1.64 percent lower - AD HOC NEWS
Lilly CEO says state needs to emphasize quality of life, health care - Inside INdiana Business
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Eli Lilly breaks ground on $6.5 billion Houston pharmaceutical plant - houston.culturemap.com
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year - 24/7 Wall St.
0.20%
0.29%
大文字化:
|
ボリューム (24 時間):